Drug Approval | February 22, 2022
UK MHRA approves Marksans All in One oral solution
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Sputnik Light can become a major booster for those vaccinated with inactivated Chinese Covid-19 vaccines globally after China has officially recommended mix & match approach with adenoviral vector-based vaccines as boosters
The grants are expected to be received over the next three years, commencing March 2022
This decision does not impact the ongoing AReSVi 006 phase III trial for RSV older adults.
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Subscribe To Our Newsletter & Stay Updated
